From data generation to policy action: HPP partners with HealthLumen

The Health Policy Partnership is partnering with HealthLumen, which specialises in precision epidemiological modelling, to quantify the current and future health and economic burden of non-communicable diseases and rare genetic conditions.

Health systems face growing pressure to decide where to invest. Making the case for change depends on two things: credible evidence of what a disease costs people, health systems and economies; and a clear route to turning that evidence into policy and practice.

The two organisations bring complementary strengths to address this need. HealthLumen’s microsimulation-based modelling platform generates evidence to show how non-communicable and rare genetic diseases develop, quantifying the health and economic consequences and the impact of proposed interventions.

HPP brings its knowledge of the wider health policy landscape and an expert-led approach that incorporates the perspectives of clinicians, patient organisations and policymakers into the interpretation and application of the modelling, and the policy implications.

HPP CEO Jody Tate said: ‘Policymakers need to know not only that a problem exists, but what it will cost if we fail to act. Our partnership with HealthLumen brings forward-looking evidence on disease burden together with our policy and system-shaping expertise, giving our clients a stronger foundation for change.’

Laura Webber, COO and Co-founder of HealthLumen, said: ‘Our models show how disease burden changes over time, and the potential impact of different interventions on long-term outcomes. Working with HPP brings that evidence together with a deep understanding of the policy landscape, helping to ensure the findings are relevant to the decisions policymakers are facing.’

Together, HPP and HealthLumen are supporting our clients to build a compelling, evidence-based case for health system change.

Get in touch to explore how our partnership can support you.